CN111407887B - Cyclooxygenase-targeted near-infrared dye metal complex photosensitizer and preparation and application thereof - Google Patents
Cyclooxygenase-targeted near-infrared dye metal complex photosensitizer and preparation and application thereof Download PDFInfo
- Publication number
- CN111407887B CN111407887B CN201811554973.4A CN201811554973A CN111407887B CN 111407887 B CN111407887 B CN 111407887B CN 201811554973 A CN201811554973 A CN 201811554973A CN 111407887 B CN111407887 B CN 111407887B
- Authority
- CN
- China
- Prior art keywords
- cyclooxygenase
- substituted
- infrared dye
- group
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 83
- 150000004696 coordination complex Chemical class 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 50
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 239000003446 ligand Substances 0.000 claims abstract description 35
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims abstract description 23
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000002184 metal Substances 0.000 claims abstract description 21
- 229910052751 metal Inorganic materials 0.000 claims abstract description 21
- 150000002500 ions Chemical class 0.000 claims abstract description 11
- 230000007935 neutral effect Effects 0.000 claims abstract description 10
- 125000000129 anionic group Chemical group 0.000 claims abstract description 8
- 229960000905 indomethacin Drugs 0.000 claims abstract description 8
- 125000005647 linker group Chemical group 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- -1 alkylidene aryl Chemical group 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 25
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- VQGHOUODWALEFC-UHFFFAOYSA-N 2-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- JVZRCNQLWOELDU-UHFFFAOYSA-N gamma-Phenylpyridine Natural products C1=CC=CC=C1C1=CC=NC=C1 JVZRCNQLWOELDU-UHFFFAOYSA-N 0.000 claims description 5
- 229910052741 iridium Inorganic materials 0.000 claims description 5
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229910052762 osmium Inorganic materials 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 229910052702 rhenium Inorganic materials 0.000 claims description 5
- 229910052703 rhodium Inorganic materials 0.000 claims description 5
- 229910052707 ruthenium Inorganic materials 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 125000005275 alkylenearyl group Chemical group 0.000 claims 12
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 230000008685 targeting Effects 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 10
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 238000003384 imaging method Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000004393 prognosis Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 description 37
- 239000000975 dye Substances 0.000 description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 26
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 22
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 22
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 22
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 20
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 19
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 17
- 238000002428 photodynamic therapy Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 12
- 125000002947 alkylene group Chemical group 0.000 description 12
- 239000004305 biphenyl Substances 0.000 description 11
- 235000010290 biphenyl Nutrition 0.000 description 11
- 229910052794 bromium Inorganic materials 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 11
- 229910052740 iodine Inorganic materials 0.000 description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 8
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 8
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 8
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 6
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 6
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005281 excited state Effects 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229940107698 malachite green Drugs 0.000 description 5
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 3
- 235000017491 Bambusa tulda Nutrition 0.000 description 3
- 241001330002 Bambuseae Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000011425 bamboo Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 3
- 229940099500 cystamine Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 description 3
- 239000001046 green dye Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- SMPJZGCAUYUJJE-UHFFFAOYSA-N 4'-methyl-2,2'-bipyridine-4-carboxaldehyde Chemical compound CC1=CC=NC(C=2N=CC=C(C=O)C=2)=C1 SMPJZGCAUYUJJE-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- WAVOOWVINKGEHS-UHFFFAOYSA-N 3-(diethylamino)phenol Chemical compound CCN(CC)C1=CC=CC(O)=C1 WAVOOWVINKGEHS-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 241000253387 Rhodobiaceae Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000907663 Siproeta stelenes Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical class C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention provides a cyclooxygenase-targeted near-infrared dye metal complex photosensitizer and preparation and application thereof. The structure of the photosensitizer is shown as the following formula (I): m (L) 1 ) m (L 2 ) n (X 1 ) o (I) (ii) a Wherein M is a nonradioactive metal with an atomic number greater than 40; l is 1 Is a neutral or anionic ligand; l is a radical of an alcohol 2 The structure is as follows: r is 1 ‑L 3 ‑R 2 Wherein R is 1 Is a cyclooxygenase-targeting compound radical, L 3 Is a linking group, R 2 Is a near infrared dye group; x 1 Is a counter ion; m and n are integers greater than or equal to 1 respectively; o is an integer of 0 to 4; the cyclooxygenase targeting compound comprises: indomethacin and indomethacin derivatives; the near-infrared dye comprises: rhodamine and rhodamine derivatives. The photosensitizer integrates the functions of tumor targeting, tumor imaging, drug tumor treatment, prognosis monitoring and the like, and is a multifunctional organic micromolecule photosensitizer.
Description
Technical Field
The invention relates to the field of photosensitizers, and particularly relates to an epoxidase-targeted near-infrared dye metal complex photosensitizer as well as preparation and application thereof.
Background
In 2008, the number of cancer deaths worldwide reaches 760 million (about 13% of all deaths). Nearly 1300 million cancer cases are newly diagnosed each year, and the number of deaths due to cancer is expected to reach 1310 ten thousand by 2030. Although regular screening and monitoring and early intervention are the best methods to improve survival, there is still a need to try to find better cancer treatment regimens, one that is both effective and efficient, acceptable and affordable to patients.
Chemotherapy, radiation therapy and surgical resection are the common cancer treatment options, chemotherapy, and recently small molecule-based therapies and immunotherapy combined with the above have emerged. However, chemotherapy often causes systemic side effects, surgical removal of tumors is associated with a high rate of recurrence, and the cumulative radiation dose limits the efficacy of radiation therapy.
Improvements to traditional medical protocols are important, but efforts should be made to develop safe, effective and cost-effective alternatives. Photodynamic therapy (PDT) is an alternative with tumor ablation and functional preservation. PDT was born in the beginning of the 20 th century and was first systematically described by Dougherty et al in 1975; since this time, PDT has been extensively studied and now PDT has become a specific disease treatment modality. In general, the process of PDT involves the use of a Photosensitizer (PS) that localizes the tumor, and then locally illuminating the tumor with light of a particular wavelength to activate the PS. And the excited PS then transfers its energy to molecular oxygen, thereby generating cytotoxic Reactive Oxygen Species (ROS), such as singlet oxygen (c 1 O 2 ) It can oxidize key macromolecules within the cell, leading to tumor cell ablation. In order not to damage adjacent normal tissues by ionizing light, which causes systemic toxicity and radiation therapy, unlike chemotherapeutic drugs, PDT uses 3 non-toxic components, which themselves have no toxic effect on biological systems. Indeed, PDT has its own advantages over conventional treatments, such as its minimal invasiveness, its repeated use without cumulative toxicity, excellent function and therapeutic effect, reduced long-term morbidity, and improved patient quality of life. PDT has been proven effective in the past four decades in superficial bladder cancer, early and obstructive lung cancer, esophageal cancer, head and neck cancer, skin cancer as well as it has been used as a post-operative adjuvant treatment to resect tumors to reduce residual tumor burden. Despite the increasing widespread use of PDT, PDT has not been achieved as a first-line tumor due to certain limitations (including lack of an ideal PS, challenges in formulating a PS, lack of dosimetry needed for complete and effective treatment, difficulty in formulating a treatment plan and monitoring treatment response)Intervention was clinically recognized.
An ideal PS would not only accumulate specifically in tumor tissue but also be rapidly cleared from normal tissue. Amphiphilic is also an ideal property that is necessary for PS because it requires some hydrophilicity for it to reach cancer tissues unimpeded and some hydrophobicity for it to bind to target cells when administered systemically. It must also be free of dark environment toxicity, high triplet particle yield, and it needs to have sufficient triplet particle survival time in order for the triplet particle to react sufficiently with ground state oxygen or other substrates to generate sufficient ROS. Just as it is required to satisfy so many different conditions, it is difficult to find or manufacture a pharmaceutical agent that can be called an ideal PS. However, some, if not all, of the drugs are used in clinical or clinical tests.
Researchers have never stopped exploring high performance photosensitizers for a long time. The development of photosensitizers goes through roughly three stages. The first phase photosensitizers were designed and synthesized primarily on the basis of porphyrins, which were developed in the early 70 and 80 th century. Such photosensitizers were the earliest and most clinically useful class of photosensitizers. They can kill cancer cells effectively and have low dark toxicity. However, their absorption coefficients are too small and often require the injection of large amounts of photosensitizer to achieve satisfactory results. In addition, the inability to selectively kill cancer cells is one of the major limitations for their further clinical use. The second type of photosensitizer mainly develops in the later 80's of the last century, and the photosensitizer overcomes the defect of weak absorbance of the first type of photosensitizer. The photosensitizer is mainly anthraquinone, phenothiazine, xanthene, cyanine and curcumin compounds. Such photosensitizers may achieve better cancer cell selectivity by adjusting the balance between hydrophilicity and lipophilicity. However, cancer cell selectivity still needs to be further improved. Since then, the focus of research in this area has been on how to increase the cancer cell selectivity of photosensitizers. The main measures are to connect a peptide chain, an antibody and other biological guide groups which are targeted for the specificity of the tumor to the existing photosensitizer or to include the photosensitizer in some nano-carriers or carriers with cancer cell selectivity to realize the targeted therapy of the cancer cells. These constitute a third class of photosensitizers. Such photosensitizers, while exhibiting some selectivity in vitro, have limited selectivity in vivo.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention aims to provide a cyclooxygenase-targeted near-infrared dye metal complex photosensitizer, the complex provided by the invention not only has a tumor targeting effect, but also can enable near-infrared dye molecules to generate a triplet excited state through coordination with metal so as to realize diagnosis and treatment of tumors, and the photosensitizer is low in toxicity and high in selectivity.
The second purpose of the invention is to provide a preparation method of the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer.
The third purpose of the invention is to provide the application of the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer.
In order to achieve the above purpose of the present invention, the following technical solutions are adopted:
an oxidase-targeted near-infrared dye metal complex photosensitizer has a structure shown as the following formula (I): m (L) 1 ) m (L 2 ) n (X 1 ) o (I) (ii) a Wherein M is a nonradioactive metal with an atomic number greater than 40; l is 1 Is a neutral or anionic ligand; l is 2 The structure is as follows: r 1 -L 3 -R 2 Wherein R is 1 Is a cyclooxygenase-targeting compound, L 3 Is a linking group, R 2 Is a near infrared dye group; x 1 Is a counter ion; m and n are integers greater than or equal to 1 respectively; o is an integer of 0 to 4; wherein the cyclooxygenase-targeting compound comprises: indomethacin and indomethacin derivatives; the near-infrared dye comprises: rhodamine and rhodamine derivatives, boron fluoride-complexed dipyrromethene dyes (bodipy dye), and malachite green bamboo green dyes (malachite gre)en) is used.
Meanwhile, the invention also provides a preparation method of the cyclooxygenase targeted near-infrared dye metal complex photosensitizer, which comprises the following steps: will (M) p (L 1 ) q (X 6 ) r And contain L 2 Reacting a ligand structure compound to obtain a cyclooxygenase-targeted near-infrared dye metal complex photosensitizer; wherein M is a nonradioactive metal with an atomic number greater than 40; l is 1 Is a neutral or anionic ligand; l is 2 The structure is as follows: r 1 -L 3 -R 2 Wherein R is 1 Is a cyclooxygenase-targeting compound, L 3 Is a linking group, R 2 Is a near infrared dye group; x 6 Is a counter ion; p and q are integers which are more than or equal to 1 respectively; r is an integer of 0 or more; wherein the cyclooxygenase-targeting compound comprises: indomethacin and indomethacin derivatives; the near-infrared dye comprises: rhodamine and rhodamine derivatives, boron fluoride complex dipyrromethene dye (bodipy dye), and malachite green bamboo green dye (malachite green).
Furthermore, the invention also provides the application of the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer in preparing a tumor imaging agent; and/or, the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer is applied to the preparation of a tumor diagnostic agent; and/or the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer is applied to the preparation of tumor therapeutic agents.
Compared with the prior art, the invention has the following beneficial effects:
the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer provided by the invention integrates the functions of tumor targeting, tumor imaging, drug tumor treatment, prognosis monitoring and the like, is a multifunctional organic micromolecule photosensitizer, and has the following advantages:
the metal complex photosensitizer has the advantages of clear structure, stable construction, convenient synthesis method and easy control. Because the ligand structure has an indometacin structure with a tumor targeting effect, the targeting aggregation on a tumor part can be realized; meanwhile, the rhodamine group serving as the most preferable near-infrared dye molecule has the advantages of good light stability, large light absorption coefficient, high quantum yield, good water solubility and the like, active oxygen can be efficiently released to kill cancer cells after complexing with metal, and the rhodamine group has the effects of targeting, near-infrared fluorescence imaging and photodynamic therapy.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.
FIG. 1 is a reaction scheme of example 1;
FIG. 2 is a schematic diagram showing the Rho mass spectrometry detection of the intermediate of example 1;
FIG. 3 is a mass spectrometric detection of the intermediate Rho-COOH of example 1;
FIG. 4 is the intermediate IM-NH of example 1 2 Mass spectrometric detection;
FIG. 5 is a Rho-IM mass spectrometric view of the ligand of example 1;
FIG. 6 is a mass spectrometric detection of the product complex Ir-Rho-IM of example 1;
FIG. 7 is a reaction scheme of example 2;
FIG. 8 is a graph showing the comparison results of the metal-in-vitro photodynamic therapy experiment in Experimental example 1;
FIG. 9 is a graph showing the tumor targeting experiment results of the metal complex in Experimental example 2;
wherein, fig. 9(a) is a schematic diagram of in vivo fluorescence imaging distribution of the metal complex; (b) is a trend change chart of the fluorescence intensity of the metal complex living body; (c) the in vitro fluorescence imaging schematic diagram of various isolated organs and tumor tissues, and (d) the fluorescence intensity schematic diagram of various isolated organs and tumor tissues.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
In view of the defects of the existing photosensitizer in application, the invention provides a metal complex type photosensitizer compound, and by taking a near-infrared dye and a cyclooxygenase (especially cyclooxygenase-2, a substance is also a cancer cell enzyme) targeting compound as a ligand, the selectivity of the photosensitizer on cancer cells can be realized, and meanwhile, through the sum of bonds of the metal and the near-infrared dye, the near-infrared dye molecules can also generate a triplet excited state, so that the cancer cells are killed, and the dark toxicity is low.
In some embodiments of the invention, a cyclooxygenase-targeted near-infrared dye metal complex photosensitizer is provided having the structure shown in formula (I):
M(L 1 ) m (L 2 ) n (X 1 ) o (I)；
wherein M is a nonradioactive metal having an atomic number greater than 40; the metal is preferably one of Re, Ru, Os, Rh, Ir, Pd, Pt or Au, and is more preferably Ir;
ligand L 1 The ligand is neutral or anionic ligand, and can be monodentate coordinating group or coordinating atom, or bidentate, tridentate, tetradentate, pentadentate, hexadentate coordinating group, etc.
Ligand L 2 The structure is as follows: r 1 -L 3 -R 2 ；
Wherein, ligand L 2 In, R 1 Is a cyclooxygenase-targeting compound, said cyclooxygenase-targeting compound comprising: indomethacin and indomethacin derivatives;
R 2 is a near-infrared dye base, the near-infrared dye comprising: rhodamine and rhodamine derivatives, boron fluoride-complexed dipyrromethene dyes (bodipy dye), and malachite green bamboo green dyes(malachite green); preferably a rhodamine derivative.
L 3 As the linking group, a functional group (via the functional group and R) at both ends may be mentioned 1 、R 2 Bond and linkage) or a C1-C6 linear or branched alkylene group (methylene, ethylene, propylene, isopropylene, butylene, pentylene, hexylene, etc.), or a C1-C6 linear or branched heteroalkylene group (cysteamine, etc.) with a heteroatom (O, S, N, etc., preferably a disulfide bond);
the straight chain or branched chain alkyl or the straight chain or branched chain heteroalkyl can be further substituted by C1-C5 alkyl and alkoxy.
X 1 The metal complex photosensitizer provided by the invention can be a neutral metal complex or an ionic metal complex as a counter ion;
when the metal complex photosensitizer provided by the invention is an ionic complex (the central metal atom of the complex cannot reach charge balance through a coordination group), a balance (anion) ion exists in the complex provided by the invention, and the balance ion can be a halogen ion, such as Cl - 、Br - 、I - Etc. may be PF 4 -a plasma radical;
m and n are integers greater than or equal to 1 respectively;
when m and n are more than 1, different L 1 、L 2 Groups which may be independently of the same or different structures;
o is an integer of 0 to 4;
the metal complex photosensitizer provided by the invention at least comprises one L 1 And one L 2 Ligands, and by the central metal with the appropriate amount L 1 、L 2 Coordination, such that the metal complex has a stable coordination structure, e.g., when the central metal is Ir, a hexa-coordination structure needs to be achieved; when the central metal is Pd 2+ 、Pt 2+ Then four coordination is often required to achieve a stable structure.
Similarly, o is also chosen such that the overall complex remains charge balanced to achieve a stable structure (e.g., o is 0 if the complex is a neutral complex overall; if the complex is still positive after all ligands have been coordinated, an appropriate number of counterions is required to maintain charge balance).
In some preferred embodiments of the invention, the ligand L 1 Includes a first ring and a second ring respectively bonded to the metal; wherein the first and second rings may be directly bonded or connected by an alkyl chain of C1-C3.
The first ring and the second ring are respectively and independently selected from one of imidazole, benzene, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, oxazole, thiazole, oxadiazole, thiadiazole, furan or thiophene.
Wherein any hydrogen atom on the first and second rings is independently optionally substituted or unsubstituted;
when the hydrogen atom on the first ring and/or the second ring is substituted, the substituent may be one or more of an alkyl group of C1 to C6 (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), an aryl group of C5 to C12 (e.g., phenyl, biphenyl, etc.), (C1 to C4 alkylene) -C5 to C12 aryl group, C1 to C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is more than 1, different substituents may be independently the same or different.
Simultaneously, the first ring and the second ring are each independently optionally fused or non-fused to a third ring;
when the first ring and/or the second ring is fused with the optional third ring, a corresponding fused ring group, for example, one of naphthalene, quinoline, benzoxazole, benzofuran, benzopyridazine, benzopyrazinyl (quinoxaline), and the like, may be formed.
In some preferred embodiments of the invention, the ligand L 1 Is an anionic ligand and comprises at least one metal bond and phenyl/substituted phenyl segment structure and one metal bond and heterocyclyl segment structure.
In some more preferred embodiments of the invention, ligand L 1 The structure is shown as the following formula (II):
in the formula (II), R 3 -R 9 Each independently is any one of hydrogen, halogen (Cl, Br, I), substituted or unsubstituted straight or branched C1-C12 alkyl (such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, octyl, heptyl, dodecyl and the like), substituted or unsubstituted straight or branched C1-C12 heteroalkyl, substituted or unsubstituted C1-C5 alkoxy (methoxy, ethoxy, propoxy and the like), substituted or unsubstituted C5-C12 aryl (cyclopentadienyl, phenyl, naphthyl and the like), substituted or unsubstituted (C1-C4) alkylene-C5-C12 aryl, substituted or unsubstituted C5-C12 heteroaryl, or substituted or unsubstituted (C1-C4) alkylene-C5-C12 heteroaryl;
the substituent of the substituted linear or branched C1-C12 alkyl group, C1-C12 heteroalkyl group, C1-C5 alkoxy group, C5-C12 aryl group, (C1-C4) alkylene-C5-C12 aryl group, C5-C12 heteroaryl group, (C1-C4) alkylene-C5-C12 heteroaryl group may be one or more of C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl group (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl group, C1-C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is greater than 1, the different substituents may independently be the same or different.
At the same time, R 3 -R 9 Any adjacent R groups in (a) optionally form a saturated or unsaturated ring and form a fused ring with the attached phenyl/heterocyclic ring.
X 2 Is N or C-R 10 ；
Wherein, when X 2 Is C-R 10 When R is 10 Is hydrogen, halogen, substituted or unsubstituted straight or branched C1-C12 alkyl (e.g., methyl, ethyl, propyl, butyl, isobutyl, pentyl, octyl, heptyl, dodecyl, etc.), substituted or unsubstituted straight or branched C1-C12 heteroalkyl, substituted or unsubstituted C1-C5 alkoxy (methoxy, ethoxy, propoxy, etc.), substituted or unsubstituted C5-C12 aryl (cyclopentadienyl, phenyl, naphthyl, etc.)) Any of substituted or unsubstituted (C1-C4) alkylene-C5-C12 aryl, substituted or unsubstituted C5-C12 heteroaryl, or substituted or unsubstituted (C1-C4) alkylene-C5-C12 heteroaryl;
the substituent of the substituted linear or branched C1-C12 alkyl group, C1-C12 heteroalkyl group, C1-C5 alkoxy group, C5-C12 aryl group, (C1-C4) alkylene-C5-C12 aryl group, C5-C12 heteroaryl group, (C1-C4) alkylene-C5-C12 heteroaryl group may be one or more of C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl group (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl group, C1-C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is greater than 1, the different substituents may independently be the same or different.
Wherein, when X 2 Is C-R 10 When R is 3 -R 10 Any adjacent R group in (a) optionally forms a saturated or unsaturated ring and forms a fused ring with the attached benzene/heterocyclic ring, for example, a fused ring structure of naphthalene, quinoline, benzoxazole, benzofuran, benzopyridazine, benzopyrazine (quinoxaline), etc.
In still further preferred embodiments of the present invention, there are provided metal complex photosensitizers having the structure:
in the complex of the above formula (VI), each atom/group (substituent, L) 2 Etc.), reference is made to the statements made above for the formulae (I), (II);
in particular, in the complex with the above structure, M is one of Re, Ru, Os, Rh, Ir, Pd, Pt or Au, and is preferably Ir.
In some preferred embodiments of the invention, L 2 The structure is shown as the following formula (III):
R 11 -R 14 、R 16 -R 26 each independently is any one of hydrogen, halogen (Cl, Br, I), substituted or unsubstituted straight or branched C1-C12 alkyl (such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, octyl, heptyl, dodecyl and the like), substituted or unsubstituted straight or branched C1-C12 heteroalkyl, substituted or unsubstituted C1-C5 alkoxy (methoxy, ethoxy, propoxy and the like), substituted or unsubstituted C5-C12 aryl (cyclopentadienyl, phenyl, naphthyl and the like), substituted or unsubstituted (C1-C4) alkylene-C5-C12 aryl, substituted or unsubstituted C5-C12 heteroaryl, or substituted or unsubstituted (C1-C4) alkylene-C5-C12 heteroaryl;
the substituent of the substituted linear or branched C1-C12 alkyl group, C1-C12 heteroalkyl group, C1-C5 alkoxy group, C5-C12 aryl group, (C1-C4) alkylene-C5-C12 aryl group, C5-C12 heteroaryl group, (C1-C4) alkylene-C5-C12 heteroaryl group may be one or more of C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl group (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl group, C1-C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is greater than 1, the different substituents may independently be the same or different.
At the same time, R 16 -R 26 Any adjacent R group in (a) optionally forms a saturated or unsaturated ring and forms a fused ring with the attached benzene/heterocyclic ring, for example, a fused ring structure of naphthalene, quinoline, benzoxazole, benzofuran, benzopyridazine, benzopyrazine (quinoxaline), etc.
R 15 For bonding to the metal and the coordinating group, for example, any of phenylpyridine, bipyridine, quinoline, or isoquinolinyl may be used.
Wherein, any hydrogen atom on the phenylpyridine, bipyridine, quinoline, or isoquinolinyl group is independently and optionally substituted or unsubstituted;
when the above groups have substituents, the substituents may be one or more of C1-C6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl, C1-C5 alkoxy (methoxy, ethoxy, etc.), etc., and when the number of substituents is more than 1, different substituents may independently be the same or different.
X 3 Is halogen (Cl, Br, I).
X 4 、X 5 Are independently amide or ester;
L 4 is C1-C12 alkyl (preferably C1-C5 alkyl such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, isopentyl, etc.), or C1-C12 heteroalkyl containing a disulfide bond (e.g., cystamine, etc.).
In some more preferred embodiments of the invention, L 2 The structure is shown as the following formula (IV):
R 11 -R 14 、R 16 -R 32 each independently is any one of hydrogen, halogen (Cl, Br, I), substituted or unsubstituted straight or branched C1-C12 alkyl (such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, octyl, heptyl, dodecyl and the like), substituted or unsubstituted straight or branched C1-C12 heteroalkyl, substituted or unsubstituted C1-C5 alkoxy (methoxy, ethoxy, propoxy and the like), substituted or unsubstituted C5-C12 aryl (cyclopentadienyl, phenyl, naphthyl and the like), substituted or unsubstituted (C1-C4) alkylene-C5-C12 aryl, substituted or unsubstituted C5-C12 heteroaryl, or substituted or unsubstituted (C1-C4) alkylene-C5-C12 heteroaryl;
the substituent of the substituted linear or branched C1-C12 alkyl group, C1-C12 heteroalkyl group, C1-C5 alkoxy group, C5-C12 aryl group, (C1-C4) alkylene-C5-C12 aryl group, C5-C12 heteroaryl group, (C1-C4) alkylene-C5-C12 heteroaryl group may be one or more of C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl group (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl group, C1-C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is greater than 1, the different substituents may independently be the same or different.
Wherein R is 16 -R 32 Any adjacent R group in (a) optionally forms a saturated or unsaturated ring and forms a fused ring with the attached benzene/heterocyclic ring, for example, a fused ring structure of naphthalene, quinoline, benzoxazole, benzofuran, benzopyridazine, benzopyrazine (quinoxaline), etc.
X 3 Is halogen (Cl, Br, I).
X 4 、X 5 Are respectively independent amide group or ester group.
L 4 Is C1-C12 alkyl (preferably C1-C5 alkyl such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, isopentyl, etc.), or C1-C12 heteroalkyl containing a disulfide bond (e.g., cystamine, etc.).
In still further preferred embodiments of the present invention, there are provided metal complex photosensitizers having the structure:
in the complex of the above formula (VII), each atom/group (substituent, L) 2 Etc.), reference is made to the statements made above for the formulae (I), (II), (III);
in particular, in the complex with the above structure, M is one of Re, Ru, Os, Rh, Ir, Pd, Pt or Au, and is preferably Ir.
In some of the most preferred embodiments of the invention,
the structure of the near-infrared dye metal complex photosensitizer is shown as the following formula (V):
wherein, in the formula (V), M is one of Re, Ru, Os, Rh, Ir, Pd, Pt or Au, and is preferably Ir.
R 3 -R 9 Each independently is any one of hydrogen, halogen (Cl, Br, I), substituted or unsubstituted straight chain or branched C1-C12 alkyl (such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, octyl, heptyl, dodecyl and the like), substituted or unsubstituted straight chain or branched C1-C12 heteroalkyl, substituted or unsubstituted C1-C5 alkoxy (methoxy, ethoxy, propoxy and the like), substituted or unsubstituted C5-C12 aryl (cyclopentadienyl, phenyl, naphthyl and the like), substituted or unsubstituted (C1-C4) alkylene-C5-C12 aryl, substituted or unsubstituted C5-C12 heteroaryl, or substituted or unsubstituted (C1-C4) alkylene-C5-C12 heteroaryl;
the substituent of the substituted linear or branched C1-C12 alkyl group, C1-C12 heteroalkyl group, C1-C5 alkoxy group, C5-C12 aryl group, (C1-C4) alkylene-C5-C12 aryl group, C5-C12 heteroaryl group, (C1-C4) alkylene-C5-C12 heteroaryl group may be one or more of C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl group (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl group, C1-C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is greater than 1, the different substituents may independently be the same or different.
At the same time, R 3 -R 9 Any adjacent R groups in (a) optionally form a saturated or unsaturated ring and form a fused ring with the attached phenyl/heterocyclic ring.
X 2 Is N or C-R 10 ；
Wherein, when X 2 Is C-R 10 When R is 10 Is hydrogen, halogen, substituted or unsubstituted straight or branched chain C1-C12 alkyl (such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, octyl, heptyl, dodecyl and the like), substituted or unsubstituted straight or branched chain C1-C12 heteroalkyl, substituted or unsubstituted C1-C5 alkoxy (methoxy, ethoxy, propoxy and the like), substituted or unsubstituted C5-C12 aryl (cyclopentadienyl, phenyl, naphthyl and the like), substituted or unsubstituted (C1-C4) alkylene-C5-C12 aryl, substituted or unsubstituted C5-C12 heteroalkylAny of aryl, or substituted or unsubstituted (C1-C4) alkylene-C5-C12 heteroaryl;
the substituent of the substituted linear or branched C1-C12 alkyl group, C1-C12 heteroalkyl group, C1-C5 alkoxy group, C5-C12 aryl group, (C1-C4) alkylene-C5-C12 aryl group, C5-C12 heteroaryl group, (C1-C4) alkylene-C5-C12 heteroaryl group may be one or more of C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl group (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl group, C1-C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is greater than 1, the different substituents may independently be the same or different.
Wherein, when X 2 Is C-R 10 When R is 3 -R 10 Any adjacent R group in (a) optionally forms a saturated or unsaturated ring and forms a fused ring with the attached benzene/heterocyclic ring, for example, a fused ring structure of naphthalene, quinoline, benzoxazole, benzofuran, benzopyridazine, benzopyrazine (quinoxaline), etc.
R 11 -R 14 、R 16 -R 32 Each independently is any one of hydrogen, halogen (Cl, Br, I), substituted or unsubstituted straight or branched C1-C12 alkyl (such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, octyl, heptyl, dodecyl and the like), substituted or unsubstituted straight or branched C1-C12 heteroalkyl, substituted or unsubstituted C1-C5 alkoxy (methoxy, ethoxy, propoxy and the like), substituted or unsubstituted C5-C12 aryl (cyclopentadienyl, phenyl, naphthyl and the like), substituted or unsubstituted (C1-C4) alkylene-C5-C12 aryl, substituted or unsubstituted C5-C12 heteroaryl, or substituted or unsubstituted (C1-C4) alkylene-C5-C12 heteroaryl;
the substituent of the substituted linear or branched C1-C12 alkyl group, C1-C12 heteroalkyl group, C1-C5 alkoxy group, C5-C12 aryl group, (C1-C4) alkylene-C5-C12 aryl group, C5-C12 heteroaryl group, (C1-C4) alkylene-C5-C12 heteroaryl group may be one or more of C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl group (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl group, C1-C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is greater than 1, the different substituents may independently be the same or different.
Wherein R is 16 -R 32 Any adjacent R group in (a) may optionally form a saturated or unsaturated ring, and form a fused ring with the benzene/heterocycle to which it is attached, for example, a fused ring structure in naphthalene, quinoline, benzoxazole, benzofuran, benzopyridazine, benzopyrazinyl (quinoxaline), and the like.
X 4 、X 5 Are independently amide or ester;
L 4 is C1-C12 alkyl (preferably C1-C5 alkyl such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, isopentyl, etc.), or C1-C12 heteroalkyl containing disulfide bonds (e.g., cystamine, etc.).
In some of the most preferred embodiments of the present invention, there are provided near-infrared dye metal complex photosensitizers having the following structure:
rhodamine has the advantages of good light stability, large absorptivity, high quantum yield, good water solubility and the like, and is widely applied to the aspects of biological probes, biological markers, environmental monitoring and the like. However, the research on rhodamine and its derivatives has basically focused on fluorescence imaging, and in order to apply rhodamine and its derivatives to photodynamic therapy, they must have triplet excited states under illumination conditions. However, rhodamine and its derivative triplet state and its report on photodynamic therapy are rare. The Detty, m.r. group imparts a triplet excited state to rhodamine by introducing S and Se atoms into the rhodamine system, but the dark toxicity of these compounds is so great that their further application in photodynamic therapy is hindered.
In the preferred complex provided by the invention, a rhodamine derivative group is coordinated with a metalThereby endowing rhodamine with a strategy of generating a triplet excited state, and the compounds can be efficiently generated under illumination 1 O 2 To kill the cells and their dark toxicity is small.
Further, the invention also provides a preparation method of the metal complex photosensitizer, which comprises the following steps:
will (M) p (L 1 ) q (X 6 ) r And contain L 2 Ligand structural compound (when L2 is neutral ligand, then directly react with compound L 2 Reaction when L is 2 When the ligand is anionic, it generally contains L 2 As starting materials, e.g. HL 2 Etc.) to obtain the cyclooxygenase targeted near-infrared dye metal complex photosensitizer;
wherein, M, L 1 、L 2 Reference is made to the structures and definitions related to formulae (I), (II), (III) above;
meanwhile, p and q are integers which are more than or equal to 1 respectively; when q is greater than 1, different L 1 May independently be the same or different groups;
r is an integer of 0 or more;
X 6 the metal complex photosensitizer provided by the invention can be a neutral metal complex or an ionic metal complex as a counter ion;
when the metal complex photosensitizer provided by the invention is an ionic complex (the central metal atom of the complex cannot reach charge balance through a coordination group), a balance (anion) ion exists in the complex provided by the invention, and the balance ion can be a halogen ion, such as Cl - 、Br - 、I - Etc. may be PF 4 - Plasma balancing the ionic groups.
In some preferred embodiments of the present invention, the metal complex photosensitizers of the present invention are prepared from M 2 (X 7 ) 2 (L 1 ) 2 And contain L 2 The compound with a group structure is obtained by reaction;
wherein, X 7 Is halogen (Cl, Br, I), M, L 1 、L 2 Is as defined in formula (I) above,
(II)、(III)。
In some more preferred embodiments of the present invention, the metal complex photosensitizers of the present invention are prepared from:
wherein in formula VIII, X ═ is halogen (Cl, Br, I), and the remaining atoms or groups are as defined above with reference to formulae (I), (II), (VI); in formula (IX), the atoms or groups are as defined above with reference to formula (III).
In further preferred embodiments of the present invention, the metal complex photosensitizers of the present invention are prepared from:
wherein, in formula VIII, X ═ is halogen (Cl, Br, I), and the remaining atoms or groups are defined as above with reference to formulae (I), (II), (VI); in formula (IX), the atoms or groups are as defined above with reference to formula (IV).
In a most preferred embodiment of the present invention, the metal complex photosensitizer of the present invention is prepared from:
Wherein, ligand L 2 (R 1 -L 3 -R 2 ) Can be prepared from R 1 -X 8 (i) AndX 9 -L 3 -X 10 (ii) and R 2 -X 11 (iii) Reacting to obtain;
wherein R is 1 、R 2 、L 3 For the definition of (A) and (B), refer to formula (I) above;
X 9 、X 10 can be reacted with X 8 Or X 11 A bond and a functional group, preferably, X 9 、X 10 Is amino, hydroxy, or carboxy, X 8 And X 11 Is a corresponding carboxyl, amino, or hydroxyl group.
In some preferred embodiments of the invention, L is present 2 Ligand compound of structure consisting of
for the definition of each compound group, reference is made to the compounds of formulae (II), (III) as above.
For example, compound (v) may be reacted with compound (ii) first and then with compound (iv) to give compound (iv) containing L 2 A ligand compound of the structure.
In some more preferred embodiments of the invention, L is 2 Ligand compound of structure consisting of
For the definition of each compound group, reference is made to the compounds of formulae (II), (IV) as above.
In a particularly preferred mode of the invention, the ligand compound L 2 Comprises the following steps:
In some embodiments of the invention, compound (v) may be represented by R 33 CHO (vii) and
after reaction, the functional group is obtained through functional transformation;
wherein, in the compound (vii), R 33 Is phenylpyridine, bipyridine, quinoline, or isoquinolinyl, each of which is optionally substituted or unsubstituted with at least one hydrogen atom independently, and at least one hydrogen atom is substituted with a methyl group that is functionally converted to form a corresponding amino, hydroxyl, or carboxyl group (preferably, the methyl group is oxidized with selenium dioxide to provide the corresponding carboxyl group);
when the above groups have substituents, the substituents may be one or more of C1-C6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl, C1-C5 alkoxy (methoxy, ethoxy, etc.), etc., and when the number of substituents is more than 1, different substituents may independently be the same or different.
R 34 、R 35 Each independently is any one of hydrogen, halogen (Cl, Br, I), substituted or unsubstituted straight chain or branched C1-C12 alkyl (such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, octyl, heptyl, dodecyl and the like), substituted or unsubstituted straight chain or branched C1-C12 heteroalkyl, substituted or unsubstituted C1-C5 alkoxy (methoxy, ethoxy, propoxy and the like), substituted or unsubstituted C5-C12 aryl (cyclopentadienyl, phenyl, naphthyl and the like), substituted or unsubstituted (C1-C4) alkylene-C5-C12 aryl, substituted or unsubstituted C5-C12 heteroaryl, or substituted or unsubstituted (C1-C4) alkylene-C5-C12 heteroaryl;
the substituent of the substituted linear or branched C1-C12 alkyl group, C1-C12 heteroalkyl group, C1-C5 alkoxy group, C5-C12 aryl group, (C1-C4) alkylene-C5-C12 aryl group, C5-C12 heteroaryl group, (C1-C4) alkylene-C5-C12 heteroaryl group may be one or more of C1-C6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, etc.), C5-C12 aryl group (e.g., phenyl, biphenyl, etc.), (C1-C4 alkylene) -C5-C12 aryl group, C1-C5 alkoxy group (methoxy, ethoxy, etc.), etc., and when the number of substituents is greater than 1, the different substituents may independently be the same or different.
In a preferred embodiment of the invention, the compound (vi) may be prepared from
And with
After the reaction, the 5-position methyl function is converted (preferably, the methyl is oxidized into carboxyl);
for each compound group definition, reference is made to the compounds of formulae (IV), (viii) above.
In a particularly preferred embodiment of the invention, L 2 Ligand compound
The method comprises the following steps:
the metal complex photosensitizer obtained by any method has good tumor cell enzyme (cyclooxygenase-2) targeting and tumor cell killing characteristics, so that the metal complex photosensitizer can be used for imaging, diagnosis and treatment of tumor cells.
Example 1
Indomethacin (100mg) and 1, 4-butanediamine-Boc (100mg) and the coupling reagents EDCI, HOBt, DMAP were added to a 25mL round-bottomed flask at room temperature, and after stirring rapidly for about 0.5 hour, the solution became clear,reacting for 24 hours at room temperature, stopping the reaction, removing the solvent by spinning, purifying by using a silica gel column, dissolving a sample by using dichloromethane, loading by using a wet method, and eluting by using dichloromethane: the gradient elution of methanol from 200:1 to 10:1, spin off the solvent and concentration gave IM-NHBoc. Yield 80%, IM-NHBoc deprotected under the action of hydrochloric acid to give IM-NH 2 。
Bpy (3.27g) was first dissolved in 1, 4-dioxane (150ml), charged to a 250ml round bottom flask and SeO was added at room temperature 2 (2.174 g). Placing the mixture in N 2 Reflux in a dark environment for 24 hours (gentle reflux, 100 ℃). The mixture was then filtered hot and the solution was cooled to room temperature, then the suspension was filtered, leaving the filtrate and the solvent removed. (rotary evaporator). The residue was dissolved in ethyl acetate (100 ml. times.3), and the suspension was filtered. Further using Na 2 CO 3 (1.0M, 100ML X2) washing the filtrate and Na 2 S 2 O 5 The organic layer was washed (0.3M, 50ML X4) for 20 minutes each. And use Na 2 CO 3 The aqueous layer was adjusted to pH10 and supplemented with CH 2 Cl 2 (100ML X4) extraction of the solution followed by solvent removal gave bpy-CHO. A mixture of bpy-CHO (10mmol), 3- (diethylamino) phenol (3.4g), p-TsOH (0.258g) and acetic acid (100ml) was heated to 70 ℃ for 7 hours. The reaction was cooled to room temperature and the pH was adjusted to 7 with 10% NaOH solution. The precipitate was filtered and washed with water (100 ml). The solid was dissolved in DCM (100ml) and chloranil (1.23g) was added thereto. The mixture was stirred for 2 hours. After removal of the solvent, the residue was purified on column (from DCM/MeOH 100: 1) and bpy-Rho was obtained. Bpy-rho (1mmol), SeO 2 (5mmol) of dioxane (10ml) was refluxed for 24 hours to give bpy-Rho-COOH.
In a 50ml round bottom flask, bpy-Rho-COOH (200mg) and IM-NH were added 2 (200mg) and coupling reagents EDCI, HOBt, DMAP, reacting at room temperature for 24h, stopping the reaction, removing the solvent by spinning, purifying with silica gel column, dissolving the sample with dichloromethane, loading by wet method, eluting with dichloromethane: the gradient elution of methanol from 200:1 to 10:1, spin off the solvent and concentration gave Rho-IM with 25% yield. Taking 10mg of Rho-IM, and then adding 9mg of Ir 2 (dpqx) 4 -Cl 2 Adding DCM and methanol into a 25ml round-bottom flask, adding 3ml of each of DCM and methanol, refluxing at 65 ℃ for 4h, adding KPF 626 mg, reacting at room temperature for 30min to generate a target product Ir-Rho-IM, and purifying.
Example 1 the reaction scheme is shown in figure 1 below.
Wherein the mass spectrum detection of intermediate Rho is shown in FIG. 2, the mass spectrum detection of intermediate Rho-COOH is shown in FIG. 3, and intermediate IM-NH 2 The mass spectrum detection map is shown in FIG. 4, the ligand Rho-IM mass spectrum detection map is shown in FIG. 5, and the product complex Ir-Rho-IM mass spectrum detection map is shown in FIG. 6.
Example 2
With reference to the procedure of example 1, Rho-IM (rhodamine-indomethacin ligand) was prepared, followed by addition of 8mg of Ir 2 (ppy) 4 -Cl 2 Adding DCM and methanol into a 25ml round-bottom flask, adding 3ml of each of DCM and methanol, refluxing at 65 ℃ for 4h, adding KPF 626 mg, reacting at room temperature for 30min, and purifying to obtain a target product Ir-Rho-IM.
Example 2 the reaction scheme is shown in figure 7.
Experimental example 1 experiment of photodynamic therapy outside metal-matched object
The product complex Ir-Rho-IM of example 1 and uncoordinated Rho-IM ligand were used as experimental materials, and the in vitro PDT treatment effect experiment was evaluated by CCK-8 analysis.
The specific experimental method comprises the following steps: under the dark condition, MCF-7 tumor cells are respectively incubated with rho-Ir-IM and rho-IM with different concentrations of 0, 0.5, 1, 2, 4, 7, 10 mu M and the like in a culture medium;
the group of culture media was irradiated with incandescent light at 11W for 30min, and then the survival rate of tumor cells in the group of culture media was measured, as shown in FIG. 8.
As can be seen from the results shown in FIG. 8, the survival rate of tumor cells gradually decreased with the increase in the concentration of rho-Ir-IM. The ligand rho-IM which is not chelated with the metal has little influence on the survival rate of the tumor cells, and the survival rate of the tumor cells can reach more than 80 percent even under the condition of high concentration of the ligand compound.
Experimental example 2 tumor targeting experiment with Metal Complex
The rho-Ir-IM product of example 1 is used as an experimental material, and the tumor targeting of the compound is tested by adopting an experimental method of living body near infrared fluorescence imaging (NIRF).
The constructed subcutaneous tumor-transplanted mouse model is injected with a metal complex rho-Ir-IM photosensitizer in the tail vein, and the change of the living fluorescence distribution and the fluorescence intensity trend is observed 48 hours after the injection, and the result is shown in figure 9.
From the NIRF image results of fig. 9a and b, the fluorescence intensity of rho-Ir-IM at the tumor site was steadily increased, and the highest peak was the strongest at 24 hours after i.v. injection.
The results of in vitro NIRF imaging of various ex vivo organs and tumor tissues after 24h injection are shown in fig. 9c, d. As can be seen from FIGS. 9c and d, the rho-Ir-IM of the present invention exhibits superior tumor tissue accumulation and relatively low uptake by various organs, further indicating that it has good targeting to tumor cells.
While particular embodiments of the present invention have been illustrated and described, it would be obvious that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Claims (9)
1. The cyclooxygenase-targeted near-infrared dye metal complex photosensitizer is characterized in that the structure of the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer is shown as the following formula (I):
M(L 1 ) m (L 2 ) n (X 1 ) o (I)；
wherein M is a nonradioactive metal with an atomic number greater than 40;
L 1 is a neutral or anionic ligand;
L 2 the structure is as follows: r 1 -L 3 -R 2 Wherein R is 1 Is a cyclooxygenase-targeting compound, L 3 Is a linking group, R 2 Is a near infrared dye group;
X 1 is a counter ion;
m and n are integers greater than or equal to 1 respectively;
o is an integer of 0 to 4;
wherein the cyclooxygenase-targeting compound comprises: indomethacin and indomethacin derivatives;
the near-infrared dye comprises: rhodamine and rhodamine derivatives;
L 2 the structure is shown as the following formula (III):
R 11 -R 14 、R 18 、R 20 -R 23 、R 25 -R 26 each independently is any one of hydrogen, halogen, substituted or unsubstituted straight chain or branched alkyl, substituted or unsubstituted straight chain or branched heteroalkyl, aryl, alkylene aryl, heteroaryl or alkylene heteroaryl;
R 16 is any one of substituted or unsubstituted alkylene aryl or alkylene heteroaryl;
R 17 、R 19 、R 24 is any one of hydrogen, halogen, unsubstituted linear or branched alkyl, unsubstituted linear or branched heteroalkyl, aryl, alkylenearyl, heteroaryl, or alkyleneheteroaryl;
R 15 is any one of phenylpyridine, bipyridine, quinoline, or isoquinolinyl;
wherein any hydrogen atom on the phenylpyridine, bipyridine, quinoline, or isoquinolinyl group is independently optionally substituted or unsubstituted;
X 3 is halogen;
X 4 、X 5 are respectively independent amide group or ester group;
L 4 is an alkyl group, or a heteroalkyl group containing a disulfide bond.
2. The cyclooxygenase-targeted near-infrared dye metal complex photosensitizer of claim 1, wherein M is selected from one of Re, Ru, Os, Rh, Ir, Pd, Pt, or Au.
3. The cyclooxygenase-targeted near-infrared dye metal complex photosensitizer of claim 1, wherein L is 1 Includes a first ring and a second ring respectively bonded to the metal;
the first ring and the second ring are respectively and independently selected from one of imidazole, benzene, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, oxazole, thiazole, oxadiazole, thiadiazole, furan or thiophene;
wherein any hydrogen atom on the first and second rings is independently optionally substituted or unsubstituted, and the first and second rings are independently optionally fused or non-fused to a third ring.
4. The cyclooxygenase-targeted near-infrared dye metal complex photosensitizer of claim 3, wherein L is 1 The structure is shown as the following formula (II):
in the formula (II), R 3 -R 9 Each independently is any one of hydrogen, halogen, substituted or unsubstituted straight chain or branched chain alkyl, substituted or unsubstituted straight chain or branched chain heteroalkyl, aryl, alkylidene aryl, heteroaryl or alkylidene heteroaryl;
wherein R is 3 -R 9 Any adjacent R groups in (a) optionally form a saturated or unsaturated ring;
X 2 is N or C-R 10 ；
R 10 Is any one of hydrogen, halogen, substituted or unsubstituted straight or branched chain alkyl, straight or branched chain heteroalkyl, alkoxy, aryl, alkylenearyl, heteroaryl, or alkyleneheteroarylSeed growing;
wherein, when X 2 Is C-R 10 When R is 3 -R 10 Any adjacent R groups in (a) optionally form a saturated or unsaturated ring.
5. The cyclooxygenase-targeted near-infrared dye metal complex photosensitizer of claim 1, wherein L is 2 The structure is shown as the following formula (IV):
R 11 -R 14 、R 18 、R 20 -R 23 、R 25 -R 26 each independently is any one of hydrogen, halogen, substituted or unsubstituted straight chain or branched chain alkyl, substituted or unsubstituted straight chain or branched chain heteroalkyl, aryl, alkylene aryl, heteroaryl or alkylene heteroaryl;
R 16 is any one of substituted or unsubstituted alkylene aryl or alkylene heteroaryl;
R 17 、R 19 、R 24 is any one of hydrogen, halogen, unsubstituted linear or branched alkyl, unsubstituted linear or branched heteroalkyl, aryl, alkylenearyl, heteroaryl, or alkyleneheteroaryl;
X 3 is halogen;
X 4 、X 5 are respectively independent amide group or ester group;
L 4 is an alkyl group, or a heteroalkyl group containing a disulfide bond.
6. The cyclooxygenase-targeted near-infrared dye metal complex photosensitizer according to any one of claims 1 to 5, characterized in that the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer has the following structure (V):
wherein, in the formula (V), R 3 -R 9 Each independently is any one of hydrogen, halogen, substituted or unsubstituted straight chain or branched chain alkyl, substituted or unsubstituted straight chain or branched chain heteroalkyl, aryl, alkylene aryl, heteroaryl or alkylene heteroaryl;
wherein R is 3 -R 9 Any adjacent R groups in (a) optionally form a saturated or unsaturated ring;
X 2 is N or C-R 10 ；
R 10 Is any one of hydrogen, halogen, substituted or unsubstituted straight or branched chain alkyl, substituted or unsubstituted straight or branched chain heteroalkyl, aryl, alkylenearyl, heteroaryl, or alkyleneheteroaryl;
wherein, when X 2 Is C-R 10 When R is 3 -R 10 Optionally forming a saturated or unsaturated ring;
R 11 -R 14 、R 18 、R 20 -R 23 、R 25 -R 26 each independently is any one of hydrogen, halogen, substituted or unsubstituted straight chain or branched chain alkyl, substituted or unsubstituted straight chain or branched chain heteroalkyl, aryl, alkylene aryl, heteroaryl or alkylene heteroaryl;
R 16 is any one of substituted or unsubstituted alkylene aryl or alkylene heteroaryl;
R 17 、R 19 、R 24 is any one of hydrogen, halogen, unsubstituted linear or branched alkyl, unsubstituted linear or branched heteroalkyl, aryl, alkylenearyl, heteroaryl, or alkyleneheteroaryl;
X 3 is halogen;
X 4 、X 5 are independently amide or ester;
L 4 is an alkyl group, or a heteroalkyl group containing a disulfide bond.
7. The cyclooxygenase-targeted near-infrared dye metal complex photosensitizer according to any one of claims 1 to 5, characterized in that the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer has the following structure:
8. the method of making a cyclooxygenase-targeted near-infrared dye metal complex photosensitizer of any one of claims 1-7, comprising:
will (M) p (L 1 ) q (X 6 ) r And contain L 2 Reacting a ligand structure compound to obtain a cyclooxygenase-targeted near-infrared dye metal complex photosensitizer;
wherein M is a nonradioactive metal having an atomic number greater than 40;
L 1 is a neutral or anionic ligand;
L 2 the structure is as follows: r 1 -L 3 -R 2 Wherein R is 1 Is a cyclooxygenase-targeting compound, L 3 Is a linking group, R 2 Is a near infrared dye group;
X 6 is a counter ion;
p and q are integers which are more than or equal to 1 respectively;
r is an integer of 0 or more;
wherein the cyclooxygenase-targeting compound comprises: indomethacin and indomethacin derivatives;
the near-infrared dye comprises: rhodamine and rhodamine derivatives.
9. Use of the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer of any one of claims 1 to 7 in the preparation of a tumor imaging agent;
and/or, the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer is applied to the preparation of a tumor diagnostic agent;
and/or the cyclooxygenase-targeted near-infrared dye metal complex photosensitizer is applied to the preparation of tumor therapeutic agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811554973.4A CN111407887B (en) | 2018-12-18 | 2018-12-18 | Cyclooxygenase-targeted near-infrared dye metal complex photosensitizer and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811554973.4A CN111407887B (en) | 2018-12-18 | 2018-12-18 | Cyclooxygenase-targeted near-infrared dye metal complex photosensitizer and preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111407887A CN111407887A (en) | 2020-07-14 |
| CN111407887B true CN111407887B (en) | 2022-09-20 |
Family
ID=71484883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811554973.4A Active CN111407887B (en) | 2018-12-18 | 2018-12-18 | Cyclooxygenase-targeted near-infrared dye metal complex photosensitizer and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111407887B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734963B2 (en) * | 2008-10-02 | 2014-05-27 | Basf Se | Complex salts |
| US20120065614A1 (en) * | 2010-09-10 | 2012-03-15 | University Of North Texas | Polyionic transitional metal phosphorescent complex/polymer hybrid systems for bioimaging and sensing applications |
| CN106188149B (en) * | 2016-07-05 | 2019-03-22 | 上海师范大学 | A kind of near-infrared metal iridium complex and its preparation method and application |
| CN108276454B (en) * | 2018-01-19 | 2019-08-27 | 曲阜师范大学 | A kind of half sandwich complex of iridium with fluorescent characteristic two tooth cheland containing N^N and preparation method thereof, application |
-
2018
- 2018-12-18 CN CN201811554973.4A patent/CN111407887B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111407887A (en) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jinadasa et al. | Syntheses and cellular investigations of 173-, 152-, and 131-amino acid derivatives of chlorin e6 | |
| US5004811A (en) | Tetrapyrrole aminocarboxylic acids | |
| JP5823413B2 (en) | Process for the preparation of novel porphyrin derivatives and their use as PDT agents and fluorescent probes | |
| EP1246826B1 (en) | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them | |
| CN110003461B (en) | Polyiodide-modified BODIPY derivative and preparation method and application thereof | |
| EP2940021B1 (en) | Cyanine dye compound and preparation method therefor, and dual-function agent for photodynamic therapy and preparation method therefor | |
| JP4733126B2 (en) | Addendum of fluorescent dye and tumor affinity tetrapyrrole | |
| CN113683602B (en) | Heptamethine cyanine micromolecule for multi-modal treatment of hypoxic tumors, and preparation method and application thereof | |
| US9155791B2 (en) | Metallation enhancements in tumor-imaging and PDT therapy | |
| Liu et al. | A novel heptamethine cyanine photosensitizer for FRET-amplified photodynamic therapy and two-photon imaging in A-549 cells | |
| JP6911197B2 (en) | Derivatives in which both the peri-position and 2-position of hypoclerin are amino-substituted, the preparation method thereof, and a photosensitizer containing the same. | |
| Liu et al. | A near-infrared and lysosome-targeted BODIPY photosensitizer for photodynamic and photothermal synergistic therapy | |
| CN113527319A (en) | Novel chlorin e4Derivative and pharmaceutically acceptable salt thereof, and preparation method and application thereof | |
| CN111407887B (en) | Cyclooxygenase-targeted near-infrared dye metal complex photosensitizer and preparation and application thereof | |
| CN114045045B (en) | Single-photon up-conversion pentamethine cyanine photosensitive dye, and preparation method and application thereof | |
| CN113788848B (en) | Phthalocyanine-artemisinin conjugate used as sonodynamic/photodynamic sensitizer and preparation method and application thereof | |
| CN114656450A (en) | Preparation method and application of N ^ N ^ N ligand with ultraviolet-visible absorption and fluorescence luminescence characteristics | |
| CN111943954B (en) | Dihydroporphin derivative and corresponding preparation method and application thereof | |
| CN107789623B (en) | Piperazine substituted silicon phthalocyanines and their use in photothermal therapy | |
| KR101842633B1 (en) | Diagnostic or therapeutic composition of cancer which is activated by cathepsin B, and near-infrared imaging and phototherapy of tumor using the same | |
| CN113717183B (en) | Phthalocyanine modified by pericyclic asymmetric arginine, preparation thereof and application thereof in pharmaceutical field | |
| EP3303344B1 (en) | Dihydropyrene derivatives, processes for preparing the same and their uses | |
| KR20180019823A (en) | Monosaccharide substituted tetrapyrazinoporphyrazine derivatives for photodynamic therapy and composition for photosensitizer comprising the same | |
| CN106632307B (en) | Benzo [ c, d ] indolodane composite cyanine and synthetic method and application thereof | |
| JP2001181184A (en) | New photochemical therapeutic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |